You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
公司新闻
公司新闻 创新速递 媒体报道
沛嘉医疗项目入选“十四五”国家重点研发计划
2025-01-08 10:50:22

科技部近日公布“十四五”国家重点研发计划“诊疗装备与生物医用材料”重点专项立项清单,其中沛嘉医疗牵头的“微创介入瓣膜新材料及器械”项目,成功入选重点研发计划。 

640.png

该项目是结构性心脏病领域的一项重大创新成果,旨在通过先进的医疗技术解决主动脉瓣狭窄及反流等严重心脏疾病的治疗难题,为患者提供更为安全、有效、耐用的治疗手段,推动心脏瓣膜疾病治疗领域的发展。 

国家重点研发计划是我国目前最高级别的研发项目,重点解决事关产业核心竞争力、国家整体自主创新能力和国家安全的战略性、基础性、前瞻性重大科学技术问题,用于突破国民经济和社会发展主要领域的技术瓶颈。此次获批立项,不仅是沛嘉医疗“硬核科研实力”的有力证明,更标志着公司在结构性心脏病医疗器械领域取得了重大突破,行业影响力与竞争力迈上新台阶。


Top